CMMB — Chemomab Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapNeutral
- $1.14m
- -$31.56m
- 13
- 59
- 43
- 30
Annual income statement for Chemomab Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | ||||
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 22.9 | 11.7 | 12.4 | 28.5 |
| Operating Profit | -22.9 | -11.7 | -12.4 | -28.5 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -27.1 | -11.6 | -12.5 | -28.2 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -27.1 | -11.6 | -12.5 | -27.6 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -27.1 | -11.6 | -12.5 | -27.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -27.1 | -11.6 | -12.5 | -27.6 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -11 | -4.68 | -0.962 | -1.94 |